These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 3107222)

  • 41. Absence of viral sequences in the WHO-Vero Cell Bank. A collaborative study.
    Horaud F
    Dev Biol Stand; 1992; 76():43-6. PubMed ID: 1478353
    [No Abstract]   [Full Text] [Related]  

  • 42. WHO Expert Committee on Biological Standardization. Thirty-sixth Report.
    World Health Organ Tech Rep Ser; 1987; 745():1-149. PubMed ID: 3111102
    [No Abstract]   [Full Text] [Related]  

  • 43. WHO Study Group on cell substrates for production of biologicals, Geneva, Switzerland, 11-12 June 2007.
    Knezevic I; Stacey G; Petricciani J;
    Biologicals; 2008 May; 36(3):203-11. PubMed ID: 18218325
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Safety of biological products prepared from mammalian cell culture. In-process testing for viral agents.
    Dev Biol Stand; 1998; 93():130-1. PubMed ID: 9737389
    [No Abstract]   [Full Text] [Related]  

  • 45. Proceedings of the Joint ESACT -- IABS meeting on the use of heteroploid and other cell substrates for the production of biologicals. Heidelberg (F.R. Germany) 18-22 May, 1981.
    Dev Biol Stand; 1981; 50():1-398. PubMed ID: 7341286
    [No Abstract]   [Full Text] [Related]  

  • 46. Risk reduction in biotherapeutic products.
    Ill CR; Dehghani H
    Curr Opin Drug Discov Devel; 2009 Mar; 12(2):296-304. PubMed ID: 19333875
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Evaluation of anti-viral filters.
    Hughes B; Bradburne A; Sheppard A; Young D
    Dev Biol Stand; 1996; 88():91-8. PubMed ID: 9119168
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Requirements for biological substances. Report of a WHO Expert Group.
    World Health Organ Tech Rep Ser; 1966; 323():3-71. PubMed ID: 4955715
    [No Abstract]   [Full Text] [Related]  

  • 49. Commentary: surveillance of reactions to biologicals.
    Hannik CA
    Bull World Health Organ; 1977; 55 Suppl 2(Suppl 2):163-5. PubMed ID: 305309
    [No Abstract]   [Full Text] [Related]  

  • 50. Mammalian cell culture systems for recombinant protein production.
    Birch JR; Froud SJ
    Biologicals; 1994 Jun; 22(2):127-33. PubMed ID: 7917229
    [No Abstract]   [Full Text] [Related]  

  • 51. Introductory remarks: viral safety of biologicals.
    Horaud F
    Dev Biol Stand; 1991; 75():3-7. PubMed ID: 1794630
    [No Abstract]   [Full Text] [Related]  

  • 52. An overview of quantitative PCR assays for biologicals: quality and safety evaluation.
    Xu Y; Brorson K
    Dev Biol (Basel); 2003; 113():89-98. PubMed ID: 14620857
    [TBL] [Abstract][Full Text] [Related]  

  • 53. International acceptance of blood and blood products.
    Petricciani JC
    Dev Biol (Basel); 2000; 102():3-8. PubMed ID: 10794085
    [TBL] [Abstract][Full Text] [Related]  

  • 54. DNA, dragons and sanity.
    Petricciani JC; Horaud FN
    Biologicals; 1995 Sep; 23(3):233-8. PubMed ID: 8527124
    [No Abstract]   [Full Text] [Related]  

  • 55. The significance of the blood-borne viruses: blood banking and transfusion medicine.
    Sherwood WC
    Dev Biol Stand; 1993; 81():25-33. PubMed ID: 8174810
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Testing human biologicals in animal host resistance models.
    Burleson GR; Burleson FG
    J Immunotoxicol; 2008 Jan; 5(1):23-31. PubMed ID: 18382855
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Genetic stability and product consistency of rDNA-derived biologicals from mammalian cells.
    Bebbington CR; Lambert K
    Dev Biol Stand; 1994; 83():183-4. PubMed ID: 7883094
    [No Abstract]   [Full Text] [Related]  

  • 58. WHO expert committee on biological standardization. Thirty-seventh report.
    World Health Organ Tech Rep Ser; 1987; 760():1-203. PubMed ID: 3124356
    [No Abstract]   [Full Text] [Related]  

  • 59. Transmissible spongiform encephalopathies and the safety of naturally-derived biologicals.
    Di Martino A
    Biologicals; 1993 Mar; 21(1):61-6. PubMed ID: 8217119
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Future directions for ensuring viral safety of biopharmaceuticals.
    Trent DW
    Dev Biol Stand; 1996; 88():333-5. PubMed ID: 9119159
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.